Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic

Wang, Ziqi; Kai, Cui; Costabel, Ulrich; Xiao-ju, Zhang

doi:10.1002/exp.20210082

Cited by 32 publications

(21 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also enhance the uptake by antigen-presenting cells. Lipids are known as an excellent transporter of nucleic acids to the cells, mainly due to their compatibility with the lipid cell membranes [ 154 ]. Although mRNA-based vaccines have never been approved, the nucleoside-modified mRNA-lipid nanoparticles (LNP) vaccine platform employed by Pfizer/BioNTech and Moderna in developing SARS-CoV-2 vaccines has extensively undergone preclinical studies for its effectiveness and supportive protective effect of the humoral immune responses [ 155 ].…”

Section: Future Perspectivementioning

confidence: 99%

COVID-19 Vaccines, Effectiveness, and Immune Responses

Abufares

Alsoud

Alqudah

et al. 2022

IJMS

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has captivated the globe’s attention since its emergence in 2019. This highly infectious, spreadable, and dangerous pathogen has caused health, social, and economic crises. Therefore, a worldwide collaborative effort was made to find an efficient strategy to overcome and develop vaccines. The new vaccines provide an effective immune response that safeguards the community from the virus’ severity. WHO has approved nine vaccines for emergency use based on safety and efficacy data collected from various conducted clinical trials. Herein, we review the safety and effectiveness of the WHO-approved COVID-19 vaccines and associated immune responses, and their impact on improving the public’s health. Several immunological studies have demonstrated that vaccination dramatically enhances the immune response and reduces the likelihood of future infections in previously infected individuals. However, the type of vaccination and individual health status can significantly affect immune responses. Exposure of healthy individuals to adenovirus vectors or mRNA vaccines causes the early production of antibodies from B and T cells. On the other hand, unhealthy individuals were more likely to experience harmful events due to relapses in their existing conditions. Taken together, aligning with the proper vaccination to a patient’s case can result in better outcomes.

show abstract

Section: Future Perspectivementioning

confidence: 99%

COVID-19 Vaccines, Effectiveness, and Immune Responses

Abufares

Alsoud

Alqudah

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…For a long period, alum adjuvant which creates a depot at the injection site was used to protect antigens and enable their prolonged exposure to activate innate cell immunity. Nanoparticles are now used as vaccine carriers, resulting in more effective vaccine delivery and antigen uptake by DC [39]. Particularly used in the context of mRNA vaccines, nanotechnologies have led to innovative and faster vaccine development that demonstrated a high efficiency [39][40][41][42].…”

Section: Taa-based Therapeutic Cancer Vaccines: Disappointments and P...mentioning

confidence: 99%

“…Nanoparticles are now used as vaccine carriers, resulting in more effective vaccine delivery and antigen uptake by DC [39]. Particularly used in the context of mRNA vaccines, nanotechnologies have led to innovative and faster vaccine development that demonstrated a high efficiency [39][40][41][42]. Recently, a novel broad-spectrum neoantigen vaccine delivery system based on β-1,3-glucan particles and derived from natural edible Saccharomyces cerevisiae showed strong activation of immune cells that inhibited tumor growth in various syngeneic mouse models [43].…”

Section: Taa-based Therapeutic Cancer Vaccines: Disappointments and P...mentioning

confidence: 99%

Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises

Ashi

Mami‐Chouaib

Corgnac

2022

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Major advances in cancer treatment have emerged with the introduction of immunotherapies using blocking antibodies that target T-cell inhibitory receptors, such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), known as immune checkpoints. However, most cancer patients do not respond to immune checkpoint blockade (ICB) therapies, suggesting the development of resistance mechanisms associated with either an insufficient number of preexisting tumor-specific T-cell precursors and/or inappropriate T-cell reactivation. To broaden clinical benefit, anti-PD-1/PD-1 ligand (PD-L1) neutralizing antibodies have been combined with therapeutic cancer vaccines based on non-mutant and/or mutant tumor antigens, to stimulate and expand tumor-specific T lymphocytes. Although these combination treatments achieve the expected goal in some patients, relapse linked to alterations in antigen presentation machinery (APM) of cancer cells often occurs leading to tumor escape from CD8 T-cell immunity. Remarkably, an alternative antigenic peptide repertoire, referred to as T-cell epitopes associated with impaired peptide processing (TEIPP), arises on these malignant cells with altered APM. TEIPP are derived from ubiquitous non-mutant self-proteins and represent a unique resource to target immune-edited tumors that have acquired resistance to cytotoxic T lymphocytes (CTLs) related to defects in transporter associated with antigen processing (TAP) and possibly also to ICB. The present review discusses tumor-associated antigens (TAAs) and mutant neoantigens and their use as targets in peptide- and RNA-based therapeutic cancer vaccines. Finally, this paper highlights TEIPP as a promising immunogenic non-mutant neoantigen candidates for active cancer immunotherapy and combination with TAA and mutant neoantigens. Combining these polyepitope cancer vaccines with ICB would broaden T-cell specificity and reinvigorate exhausted antitumor CTL, resulting in the eradication of all types of neoplastic cells, including immune-escaped subtypes.

show abstract

“…Among them, nanomedicine has achieved tremendous progress in cancer management [12][13][14]. Nanoparticles can protect the cargo from degradation and facilitate their accumulation at tumor sites through passive diffusion or active targeting, optimizing the drug biodistribution [15][16][17][18][19]. Especially in the past few years, nanocarriers that can respond to biological cues in the tumor microenvironment (TME) attracted increasing attention [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Recent advances of bioresponsive polymeric nanomedicine for cancer therapy

et al. 2022

View full text Add to dashboard Cite

A bioresponsive polymeric nanocarrier for drug delivery is able to alter its physical and physicochemical properties in response to a variety of biological signals and pathological changes, and can exert its therapeutic efficacy within a confined space. These nanosystems can optimize the biodistribution and subcellular location of therapeutics by exploiting the differences in biochemical properties between tumors and normal tissues. Moreover, bioresponsive polymer-based nanosystems could be rationally designed as precision therapeutic platforms by optimizing the combination of responsive elements and therapeutic components according to the patient-specific disease type and stage. In this review, recent advances in smart bioresponsive polymeric nanosystems for cancer chemotherapy and immunotherapy will be summarized. We mainly discuss three categories, including acidity-sensitive, redox-responsive, and enzyme-triggered polymeric nanosystems. The important issues regarding clinical translation such as reproducibility, manufacture, and probable toxicity, are also commented.

show abstract

Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic

Cited by 32 publications

References 168 publications

COVID-19 Vaccines, Effectiveness, and Immune Responses

COVID-19 Vaccines, Effectiveness, and Immune Responses

Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises

Recent advances of bioresponsive polymeric nanomedicine for cancer therapy

Contact Info

Product

Resources

About